Not quite - until now there have been no large scale studies on whether patients would really benefit from spheres as a first line treatment. A few smaller case studies have shown that patients benefited - to the point of tumour shrinkage for surgical resection. So the current results clarified that those cases are rare and not the norm.
450 patients are considered large.. this is not a "placebo trial". Its the normal treatment vs normal+spheres treatment. And it showed no statistically significant difference.
Thus far, i've not read any market release that says Sirtex sold spheres as a first line treatment. All revenue has been from salvage therapy.
- Forums
- ASX - By Stock
- SRX
- Clinical Trial Objectives
Clinical Trial Objectives, page-17
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SRX (ASX) to my watchlist
|
|||||
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $74.27M |
Open | High | Low | Value | Volume |
17.5¢ | 18.0¢ | 17.5¢ | $132.6K | 758.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 449688 | 17.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.0¢ | 955405 | 27 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 449688 | 0.175 |
5 | 1608822 | 0.170 |
1 | 18186 | 0.165 |
1 | 2577 | 0.097 |
1 | 4000 | 0.075 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 945405 | 26 |
0.185 | 38427 | 3 |
0.190 | 220025 | 8 |
0.195 | 20478 | 2 |
0.200 | 181416 | 6 |
Last trade - 15.47pm 30/08/2024 (20 minute delay) ? |
Featured News
SRX (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online